Abstract
Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1595-1601 |
| Number of pages | 7 |
| Journal | Journal of the National Cancer Institute |
| Volume | 89 |
| Issue number | 21 |
| State | Published - Nov 5 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. / Irvine, Kari R.; Chamberlain, Ronald S.; Shulman, Eliza P.; Surman, Deborah R.; Rosenberg, Steven A.; Restifo, Nicholas P.
In: Journal of the National Cancer Institute, Vol. 89, No. 21, 05.11.1997, p. 1595-1601.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
AU - Irvine, Kari R.
AU - Chamberlain, Ronald S.
AU - Shulman, Eliza P.
AU - Surman, Deborah R.
AU - Rosenberg, Steven A.
AU - Restifo, Nicholas P.
PY - 1997/11/5
Y1 - 1997/11/5
N2 - Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P
AB - Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P
UR - http://www.scopus.com/inward/record.url?scp=0030663697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030663697&partnerID=8YFLogxK
M3 - Article
C2 - 9362157
AN - SCOPUS:0030663697
VL - 89
SP - 1595
EP - 1601
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 21
ER -